Sanford Studying Immunotherapy Drug for Esophageal Cancer – Benzinga
|
Sanford Studying Immunotherapy Drug for Esophageal Cancer
Benzinga A clinical trial at Sanford Health is studying if an immunotherapy drug developed by Merck might be able to treat certain patients with advanced esophageal cancer. The Merck Keynote 181 trial is now open at Sanford. The study is exploring the Merck … |
